NCT00423644View on ClinicalTrials.gov

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

PHASE2UnknownINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

Darinaparson

420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months

Trial Locations (8)

Unknown

Glendale

Santa Barbara

Santa Rosa

West Hollywood

Bethesda

Buffalo

Charlotte

Sioux Falls

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY